NOW APPROVED
PRESCRIBING INFORMATION
Introducing
Brineura logo
Brineura™ (cerliponase alfa) is approved to slow the loss of ability to walk or crawl (ambulation) in children with symptoms of CLN2 disease who are 3 years of age and older.

Brineura is the only enzyme replacement therapy to address the cause of CLN2 disease, a form of Batten disease. This approval marks the first time that a treatment is available for any type of Batten disease.
Contact BioMarin RareConnections™
to learn how to get started with Brineura
This program provides individual support for healthcare professionals and families throughout the Brineura treatment process.
Call us: 1-866-906-6100
Call center hours: Monday-Friday 6:00 AM to 5:00 PM PST
Email us: support@biomarin-rareconnections.com
Fax us: 1-888-863-3361

For caregivers, complete and return the BioMarin RareConnections™ Patient Registration Forms to enroll.

Rare Connections logo

Register to receive updates about Brineura.

Register Now